- Home
- POLA vs APVO Comparison
POLA vs APVO Comparison
Compare POLA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- APVO
- Stock Information
- Founded
- POLA 1979
- APVO 2016
- Country
- POLA United States
- APVO United States
- Employees
- POLA N/A
- APVO N/A
- Industry
- POLA Industrial Machinery/Components
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- POLA Miscellaneous
- APVO Health Care
- Exchange
- POLA Nasdaq
- APVO Nasdaq
- Market Cap
- POLA 4.3M
- APVO 4.1M
- IPO Year
- POLA 2016
- APVO N/A
- Fundamental
- Price
- POLA $1.91
- APVO $3.00
- Analyst Decision
- POLA
- APVO Strong Buy
- Analyst Count
- POLA 0
- APVO 1
- Target Price
- POLA N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- POLA 278.0K
- APVO 6.7M
- Earning Date
- POLA 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- POLA N/A
- APVO N/A
- EPS Growth
- POLA N/A
- APVO N/A
- EPS
- POLA N/A
- APVO N/A
- Revenue
- POLA $13,918,000.00
- APVO N/A
- Revenue This Year
- POLA N/A
- APVO N/A
- Revenue Next Year
- POLA N/A
- APVO N/A
- P/E Ratio
- POLA N/A
- APVO N/A
- Revenue Growth
- POLA 8.08
- APVO N/A
- 52 Week Low
- POLA $1.53
- APVO $2.81
- 52 Week High
- POLA $4.90
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- POLA 62.97
- APVO 34.83
- Support Level
- POLA $1.82
- APVO $2.89
- Resistance Level
- POLA $1.97
- APVO $3.20
- Average True Range (ATR)
- POLA 0.16
- APVO 0.27
- MACD
- POLA 0.03
- APVO 0.24
- Stochastic Oscillator
- POLA 33.70
- APVO 10.63
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.